Merewin (Sildenafil Citrate)

Sildenafil citrate blocks the phosphodiesterase type 5 enzyme, which normally degrades cyclic GMP. By inhibiting this enzyme, cGMP levels rise, leading to smooth‑muscle relaxation in the corpus cavernosum and pulmonary arteries, thereby increasing blood flow where it is needed.

The exact dose of Merewin is determined by the prescribing clinician based on the individual’s health status, severity of the condition, and any concomitant medications. Physicians typically start with a low dose and may adjust it according to therapeutic response and tolerability.

Sildenafil citrate is not indicated for use during pregnancy or while breastfeeding. There is insufficient data on safety for the fetus or infant, so it should be avoided unless a healthcare professional determines that the potential benefit outweighs the risk.

To order Merewin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

The most common alternative in the PDE5 class is tadalafil. Both agents inhibit PDE5, but tadalafil has a longer half‑life, allowing once‑daily dosing for some patients, whereas sildenafil typically requires dosing about one hour before sexual activity. Choice depends on patient preference, duration of action needed and tolerability.

Merewin tablets should be stored at ambient temperature, below 25 °C, in their original container to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

Merewin is taken orally with a glass of water. For erectile dysfunction, it is usually taken about one hour before anticipated sexual activity and may be taken with or without food. For pulmonary arterial hypertension, dosing is typically scheduled at regular intervals as directed by a physician.

Serious risks include priapism (an erection lasting more than four hours), sudden loss of vision, sudden hearing loss, and severe cardiovascular events such as heart attack or stroke, especially in patients with pre‑existing heart disease. Immediate medical attention is required if any of these occur.

Merewin should not be used by individuals taking nitrates for chest pain, those with severe hypotension, recent myocardial infarction or stroke, uncontrolled hypertension, or significant liver impairment. Patients with known hypersensitivity to sildenafil or any of the tablet’s excipients should also avoid it.